Accendra Health, Inc. (ACH) Stock: Price, Forecast & Analyst Target
Accendra Health, Inc. (ACH) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $0.0857 (-35.08%), as of the Nov 18, 2026 trading session; market cap $6.60M. Expected results Oct 29, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and investments (classification unverified): 0.86× (cash as of Jun 30, 2026) · expected results Oct 29, 2026
Accendra Health, Inc. · ACH · NYSE · Healthcare · Medical - Distribution
Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Accendra Health (ACH)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet, weak growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Elite; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Falling.
Earnings yield is the main valuation drag relative to sector peers.
- quarterly revenue $697M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 0.17 · Piotroski F 3
Holding back: balance-sheet strain, a rich price, weak price trend
Helping: business quality
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 30 | Weak | |
| 30 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0857 | |
| Change on the day | -35.08% | |
| 52-week range | $0.0857–$5.69 | |
| Market capitalisation | $6.60M | — |
| Shares traded on the day | 3.20M | |
| Beta (volatility vs the S&P 500) | 1.53 |
Price & events
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Management outlook
As a result, and as shown on Slide 11, we have revised the 2026 full-year outlook for revenue to be between $2.45 billion and $2.55 billion, and a full-year adjusted EBITDA to be between $300 million and $320 million.
Jonathan Leon · Statement from
We expect the arrangements to go live later this year and believe they will both lower our operating cost and reduce inventory, thereby improving cash flow.
Edward Pesicka · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations can change.
Other perspectives
Council score for Accendra Health (ACH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Accendra Health (ACH), and what does it report?
Short answer
Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. Accendra Health, Inc. (ACH) is listed on NYSE. Healthcare / Medical Distribution Headquarters: 4435 Waterfront Drive, Suite 300, Glen Allen, VA. It employs 6,500 people and is led by Edward A. Pesicka. In Q3 FY2025 it reported revenue of $697M and net income of -$150M. The market values it at $6.60M.
What do the latest results show for Accendra Health (ACH)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $697M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $613.23M Jun 30, 2026
- Latest quarter · SG&A
- $243.56M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$35.15M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $613.23M | Not available | $243.56M | −$35.15M |
| Mar 31, 2026 | $627.78M | Not available | $255.23M | $22.80M |
| Dec 31, 2025 | $708.97M | Not available | $271.50M | $51.76M |
| Sep 30, 2025 | $697.26M | Not available | $265.84M | $56.36M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $613.20M Aug 10, 2026
- Latest report · revenue estimate
- $628.66M Aug 10, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 10, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 10, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 10, 2026 | $613.20M | $628.66M | −$0.1900 | −$0.0838 |
| May 11, 2026 | $627.80M | $644.18M | −$0.0400 | −$0.0600 |
| Feb 19, 2026 | $708.97M | $713.43M | $0.2100 | $0.2200 |
| Oct 30, 2025 | $697.26M | $714.79M | $0.2500 | $0.2300 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $697M | -$150M | -$1.94 (diluted) |
| Q4 FY2025 | $709M | -$56M | -$0.73 (diluted) |
| Q1 FY2026 | $628M | -$6M | -$0.08 (diluted) |
| Q2 FY2026 | $613M | -$89M | -$1.16 (diluted) |
What are the financial strengths and risks for Accendra Health (ACH)?
Short answer
Cash and investments (classification unverified) were $7.70M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$26.01M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway. The MoonshotScore pillars rate business quality as strengths. What is holding it back is balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Altman Z 0.17 · Piotroski F 3. Trailing ratios: ROA 0.2% · current ratio 0.41.
Data-derived red flags
- Listing risk — at $0.0857 the shares sit below the $1.00 minimum bid NYSE requires for continued listing.
- Financial-distress signal — its Altman Z-Score of 0.17 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$26.01M Jun 30, 2026
- Previous quarter · operating cash flow
- −$50.08M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$26.01M | −$47.59M |
| Mar 31, 2026 | −$50.08M | $72.00M |
| Dec 31, 2025 | $68.19M | −$9.28M |
| Sep 30, 2025 | −$172.52M | −$57.83M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Accendra Health (ACH)?
Short answer · as of
Current published price targets run low $1.50 · high $1.50 · consensus $1.50 · median $1.50 against a quoted price of $0.0857 (as of Nov 18, 2026).
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Efforts are constructively trending toward resolution in the third quarter, and we believe realized cash flow will improve upon conclusion.
Jonathan Leon ·
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Oct 31, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Accendra Health compare with its peers?
Short answer
Accendra Health's score ranks 7th of 7 in the bounded comparison shown, against 6 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $48.83 Nov 18, 2026 | $3.09B | 96 5-pillar Nov 18, 2026 | |
| $1084.43 Nov 18, 2026 | $125B | 92 5-pillar Nov 18, 2026 | |
| $278.35 Nov 18, 2026 | $64.3B | 88 5-pillar Nov 18, 2026 | |
| $348.28 Nov 18, 2026 | $66.5B | 86 5-pillar Nov 18, 2026 | |
| $85.69 Nov 18, 2026 | $9.47B | 73 5-pillar Nov 18, 2026 | |
| $50.62 Nov 18, 2026 | $2.40B | 63 5-pillar Nov 18, 2026 | |
| Accendra Health (ACH) — this page | $0.0857 | $6.60M | 30 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $1.50 – $1.50
- Consensus target
- $1.50
- Median target
- $1.50
Consensus record · Captured .
Measured against a quoted price of $0.0857 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 5, 2026
- Transactions
- 2
- Identified insiders
- 2
- Purchases
- 0
- Sales
- 0
- Other transactions
- 2
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 1 Period end Jun 30, 2026
- Previous quarter · holders
- 1 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Huntington National Bank | 1 |
Tracked investors
Which of the 16 named investors we follow held ACH in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ACH in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Jun 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Accendra Health (ACH)?
- Accendra Health Receives Delisting Notice From the New York Stock Exchange
- NYSE to Commence Delisting Proceedings Against Accendra Health, Inc.
- Blue Shield of California Expands Collaboration with Accendra Health
- BLUE SHIELD OF CALIFORNIA EXPANDS COLLABORATION WITH ACCENDRA HEALTH TO IMPROVE ACCESS TO HOME-BASED CARE
Common Questions About ACH (Healthcare)
These answers are editorial: 1 of these 9 answers is drawn from the ACH research dossier (written May 5, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ACH?
ACH carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Accendra Health, Inc. is a healthcare solutions company providing products and services to healthcare providers and patients.
Is ACH a good stock to buy?
Stock Expert AI does not rate ACH buy, sell or hold. Accendra Health, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ACH stock price today?
The last price recorded for Accendra Health, Inc. (ACH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ACH price target?
The analyst consensus price target for Accendra Health, Inc. (ACH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What does Accendra Health, Inc. do?
Accendra Health, Inc. operates as a healthcare solutions company, providing a range of products and services to healthcare providers and patients.
What are the key factors to evaluate for ACH?
Accendra Health, Inc. (ACH) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Accendra Health operates in two segments: Products & Healthcare Services and Patient Direct, providing a diversified revenue stream. Not financial advice.
How frequently does ACH data refresh on this page?
ACH's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ACH's recent stock price performance?
Accendra Health, Inc. (ACH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product and service offerings. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACH overvalued or undervalued right now?
Accendra Health, Inc. (ACH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 5, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 75 figures on this page — 2 from SEC filings and earnings calls, 64 from Financial Modeling Prep (FMP), 3 with no recorded source, 4 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com